Hanmi Pharm Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 5/6
Hanmi Pharm has been growing earnings at an average annual rate of 38.8%, while the Pharmaceuticals industry saw earnings growing at 11.5% annually. Revenues have been growing at an average rate of 8.1% per year. Hanmi Pharm's return on equity is 17%, and it has net margins of 11.8%.
Key information
38.8%
Earnings growth rate
39.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 8.1% |
| Return on equity | 17.0% |
| Net Margin | 11.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Risks To Shareholder Returns Are Elevated At These Prices For Hanmi Pharm. Co., Ltd. (KRX:128940)
Nov 19
Does Hanmi Pharm (KRX:128940) Have A Healthy Balance Sheet?
Nov 01Does Hanmi Pharm (KRX:128940) Deserve A Spot On Your Watchlist?
Oct 17Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 16Pinning Down Hanmi Pharm. Co., Ltd.'s (KRX:128940) P/E Is Difficult Right Now
Jul 31Do Hanmi Pharm's (KRX:128940) Earnings Warrant Your Attention?
Jul 16Hanmi Pharm (KRX:128940) Seems To Use Debt Rather Sparingly
Jun 11A Look At The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)
May 08Hanmi Pharm. Co., Ltd.'s (KRX:128940) Share Price Not Quite Adding Up
Apr 22Calculating The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)
Mar 15Hanmi Pharm (KRX:128940) Use Of Debt Could Be Considered Risky
Feb 16
What Percentage Of Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Do Insiders Own?
Jan 17Hanmi Pharm's (KRX:128940) Stock Price Has Reduced 48% In The Past Five Years
Dec 22Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate
Nov 24Revenue & Expenses Breakdown
How Hanmi Pharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,568,781 | 184,377 | 422,608 | 185,996 |
| 31 Mar 24 | 1,533,383 | 158,086 | 425,449 | 181,612 |
| 31 Dec 23 | 1,490,887 | 146,231 | 422,595 | 181,769 |
| 30 Sep 23 | 1,419,708 | 131,316 | 417,941 | 172,935 |
| 30 Jun 23 | 1,397,244 | 101,982 | 417,863 | 173,702 |
| 31 Mar 23 | 1,371,607 | 106,424 | 415,433 | 164,490 |
| 31 Dec 22 | 1,331,547 | 82,792 | 410,340 | 154,317 |
| 30 Sep 22 | 1,330,854 | 80,780 | 406,247 | 145,044 |
| 30 Jun 22 | 1,291,788 | 78,807 | 390,821 | 141,929 |
| 31 Mar 22 | 1,253,997 | 67,497 | 377,286 | 145,622 |
| 31 Dec 21 | 1,203,186 | 67,025 | 361,309 | 146,027 |
| 30 Sep 21 | 1,130,015 | 77,337 | 343,349 | 140,632 |
| 30 Jun 21 | 1,093,865 | 23,092 | 334,837 | 184,352 |
| 31 Mar 21 | 1,057,969 | 23,462 | 319,870 | 192,925 |
| 31 Dec 20 | 1,075,854 | 11,959 | 319,555 | 212,387 |
| 30 Sep 20 | 1,101,450 | -1,238 | 325,321 | 229,417 |
| 30 Jun 20 | 1,100,225 | 36,049 | 329,200 | 196,004 |
| 31 Mar 20 | 1,127,208 | 46,907 | 338,190 | 189,392 |
| 31 Dec 19 | 1,113,650 | 52,110 | 334,316 | 194,288 |
| 30 Sep 19 | 1,104,465 | 29,815 | 323,145 | 186,014 |
| 30 Jun 19 | 1,074,014 | 34,892 | 311,596 | 174,682 |
| 31 Mar 19 | 1,044,929 | 29,971 | 298,362 | 179,834 |
| 31 Dec 18 | 1,015,962 | 24,891 | 291,436 | 165,906 |
| 30 Sep 18 | 954,879 | 41,003 | 294,418 | 162,807 |
| 30 Jun 18 | 947,203 | 50,120 | 291,491 | 166,804 |
| 31 Mar 18 | 928,713 | 49,170 | 292,111 | 156,725 |
| 31 Dec 17 | 916,586 | 60,434 | 284,952 | 151,289 |
| 30 Sep 17 | 856,033 | 12,415 | 255,152 | 142,897 |
| 30 Jun 17 | 848,177 | -3,433 | 260,920 | 139,067 |
| 31 Mar 17 | 859,901 | 4,177 | 277,865 | 142,438 |
| 31 Dec 16 | 882,725 | 23,326 | 291,189 | 142,894 |
| 30 Sep 16 | 1,300,579 | 220,192 | 440,412 | 153,498 |
| 30 Jun 16 | 1,349,235 | 188,682 | 457,339 | 155,392 |
| 31 Mar 16 | 1,359,164 | 179,858 | 459,716 | 162,805 |
| 31 Dec 15 | 1,317,535 | 154,443 | 450,085 | 167,987 |
| 30 Sep 15 | 939,070 | 9,750 | 319,290 | 167,011 |
| 30 Jun 15 | 850,027 | 37,587 | 287,695 | 163,529 |
| 31 Mar 15 | 791,905 | 33,760 | 256,965 | 151,272 |
| 31 Dec 14 | 761,280 | 35,510 | 244,990 | 135,168 |
| 30 Sep 14 | 743,779 | 32,302 | 242,562 | 119,832 |
| 30 Jun 14 | 750,634 | 45,249 | 247,498 | 110,621 |
| 31 Mar 14 | 743,951 | 45,870 | 253,115 | 101,862 |
| 31 Dec 13 | 730,134 | 43,933 | 251,671 | 94,965 |
Quality Earnings: A128940 has high quality earnings.
Growing Profit Margin: A128940's current net profit margins (11.8%) are higher than last year (7.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A128940's earnings have grown significantly by 38.8% per year over the past 5 years.
Accelerating Growth: A128940's earnings growth over the past year (80.8%) exceeds its 5-year average (38.8% per year).
Earnings vs Industry: A128940 earnings growth over the past year (80.8%) exceeded the Pharmaceuticals industry 21.6%.
Return on Equity
High ROE: A128940's Return on Equity (17%) is considered low.